Biomotion Sciences Ordinary Shares
Price & Volume
Stats
See moreOpen | $1 |
Previous Close | $0.99 |
Day Range | $1-$1 |
52W Range | $0.99-$22.36 |
Market Cap | $3.4M |
Shares Short | 49,913 |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$8.96 |
News
See moreYahoo Finance • 22 days ago
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
Yahoo Finance • 4 months ago
Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer
Yahoo Finance • 5 months ago
Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer
Yahoo Finance • 5 months ago
Silexion Therapeutics GAAP EPS of -$2.88
About
CEO | Mr. Ilan Hadar M.B.A. |
CFO | Ms. Mirit Horenshtein Hadar |
Address | The Goldyne Savad Inst. of Gene Therapy, Jerusalem, Israel, 9112001 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 13 |
